NCT04802837Phase 3Terminated

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Study sponsor: Summit Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-09-17Actual
Enrollment · participants2Actual
Source updated2023-08-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.